Literature DB >> 25546725

Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma.

Massimo Dozzo1, Francesco Zaja, Stefano Volpetti, Alessandra Sperotto, Alessandro Magli, Renato Fanin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25546725     DOI： 10.1002/ajh.23925

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  2 in total

1.  Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.

Authors:  Aurore Perrot; Hélène Monjanel; Réda Bouabdallah; Philippe Quittet; Clémentine Sarkozy; Marc Bernard; Aspasia Stamatoullas; Cécile Borel; Krimo Bouabdallah; Emmanuelle Nicolas-Virelizier; Marion Fournier; Franck Morschhauser; Pauline Brice
Journal:  Haematologica       Date:  2016-01-14       Impact factor: 9.941

2.  Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.

Authors:  Stefan Schönberger; Cornelius van Beekum; Barbara Götz; Daniel Nettersheim; Hubert Schorle; Dominik T Schneider; Anna Casati; Rogerio B Craveiro; Gabriele Calaminus; Dagmar Dilloo
Journal:  J Cell Mol Med       Date:  2017-09-22       Impact factor: 5.310
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.